Navigation Links
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Date:10/19/2008

Novel Outpatient Regimen Pioneered by Investigators from Tumor Institute in

Milan

SEATTLE, Oct. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the results of an innovative study that investigated high (bone marrow ablative) dose Zevalin(R) ([90Y]-ibritumomab tiuxetan) followed by autologous stem cell infusions among 30 patients (median age 62 years) with relapsed/refractory or high risk aggressive non-Hodgkin's lymphoma (NHL) not eligible for a chemotherapy-based transplant. High-dose myeloablative chemotherapy is an effective therapy for NHL but because it is associated with significant toxicities it is usually reserved for clinically fit and younger patients and therefore is not an option for many due to the average age of NHL patients being approximately 60 years old. In this study, three cycles of conventional chemotherapy were given followed by high dose chemotherapy with a stem cell rescue and then followed by up to three times the standard dose of Zevalin with an additional stem cell rescue. This treatment regimen resulted in 83 percent of patients achieving a disease free state with a projected overall survival of 87 percent after a median follow up of 30 months.

"Our results suggest that the use of high-dose Zevalin for these patients provides a significant clinical benefit and is very well tolerated," said Alessandro M. Gianni, M.D., Full Professor of Medical Oncology and Director of the School of Specialization in Medical Oncology at the University of Milan. "We are encouraged by the outcome of the study as this regimen could be applicable to the vast majority of high risk or relapsed non-Hodgkin's lymphoma patients."

High-dose Zevalin was well tolerated and no deaths were noted with this regimen. The expected severe marrow suppression associated with myeloablative treatment was seen but patien
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
2. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
3. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
4. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
5. Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkins Lymphoma
6. Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkins Lymphoma
7. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
8. FDA Meeting Provides Green Light for Cell Therapeutics Submission of Supplemental Filing for Zevalin(R) Label Expansion
9. Tandem Labs New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
10. DW Healthcare Partners Announces the Sale of Tandem Labs
11. CardiacAssist, Inc. Surpasses 1300 TandemHeart System Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 The Alliance for ... survey of European physicians at the "1 ST ... Biological Therapies" at the Spanish Ministry of Health, ... EuropaBio and the Spanish Bioindustry Association (ASEBIO), included ... from Spanish oncology and rheumatology societies, representatives from ...
(Date:11/26/2014)... PMG Research, Inc. announced today the formation of ... sites that provide clinical research services to pharmaceutical companies and ... its partnerships with large physician practices and integrated health systems. ... the Southeastern United States and spans over 60 physician practices. ... will be held by: Dr. Robert Holmes, MD, of PMG ...
(Date:11/26/2014)... 2014 Silicon Valley Electronic Data Capture ... RPM Alliance , provider of clinical research and data ... latest addition to its CRO Partnership Program, Clinovo expands ... to India. , “We have found Clinovo’s ClinCapture ... EDC platform which is both user friendly and easy ...
(Date:11/26/2014)... 25, 2014 Global biostimulants market ... growing at an estimated CAGR of 12.5%. In ... food products with least ecological impacts, farmers are ... to boost crop yield more effectively & efficiently. ... can improve the return on investments. , Leading ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4
... surgeons, MONTVALE, N.J., June 3 ... information dedicated to enhancing the surgeon,s,practice, has ... engine tool:,SURGERYFINDIT.COM ( http://www.SURGERYFINDIT.COM )., As ... provide,general surgeons with a wealth of peer-reviewed, ...
... June 3 National Stem Cell,Holding, Inc. (Pink ... Steiner, MD, MBA, as its Chief Operating Officer. ... proven management and business skills.,After establishing a private ... medical and business consultant to numerous Fortune 500 ...
... ANGELES, June 3 Signalife, Inc. (Amex:,SGN) has ... Ehrlichman -- who is,already a member of the ... Operating Officer. In that capacity, Mr. Ehrlichman,s primary ... will be on,sales and marketing of the company,s ...
Cached Biology Technology:SURGERYFINDIT.COM and Convera(R) Launch Vertical Search Site for Surgeons 2National Stem Cell Holding Appoints Kenneth Steiner, MD, MBA, as Chief Operating Officer 2National Stem Cell Holding Appoints Kenneth Steiner, MD, MBA, as Chief Operating Officer 3Signalife Appoints Lee Ehrlichman President and Chief Operating Officer 2Signalife Appoints Lee Ehrlichman President and Chief Operating Officer 3
(Date:11/7/2014)... CORAL SPRINGS, Florida , November 6, 2014 ... improved secure authentication for better mobile security revolutionizing online transactions. ... NXTD ), Alibaba Holdings Ltd. (NYSE: BABA ), ... MSFT ), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: NXTD and NXTDW), a biometric authentication ...
(Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
(Date:11/4/2014)... – Temple University School of Medicine announced today ... an initiative funded by the Bill & Melinda ... of Obstetrics, Gynecology and Reproductive Sciences; and Vice ... University School of Medicine will pursue an innovative ... Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Temple University School of Medicine receives Grand Challenges Explorations grant 2
... at the University of Wisconsin-Madison may represent a significant ... that would use this abundant element to store and ... non-carbon, non-polluting fuel for storing intermittent energy from the ... water but no carbon dioxide. Practically speaking, producing hydrogen ...
... U.S. Department of Energy,s Brookhaven National Laboratory have identified ... human adenovirus, a cause of ailments ranging from colds ... in FEBS Letters , a journal of the ... sifted through thousands of compounds to determine which might ...
... have alteration in metabolic pathways as a result of ... 2-related factor 2) works as a "master gene" that ... pollutant-detoxifying genes to protect the lungs from variety of ... However, researchers at the Johns Hopkins Bloomberg School of ...
Cached Biology News:New catalyst could cut cost of making hydrogen fuel 2Scientists identify promising antiviral compounds 2Scientists identify promising antiviral compounds 3Hijacking stress response in cancer 2
...
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
FGF Receptor 1 Antibody...
Biology Products: